Growth factor control of bone mass

Journal of Cellular Biochemistry

Volumn 108, Issue 4, 2009, Pages 769-777

  Canalis, Ernesto ^a,b  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Differentiation; Growth factor antagonists; Growth factors; Osteoblasts; Osteoporosis

Indexed keywords

ACTIVIN; ANABOLIC AGENT; BINDING PROTEIN; BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; WNT PROTEIN;

BONE CELL; BONE MASS; CELL COUNT; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; HUMAN; MESENCHYME CELL; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE;

ANIMALS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL LINEAGE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTATION; OSTEOBLASTS; OSTEOPOROSIS; WNT PROTEINS;

EID: 70350441264     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22322     Document Type: Review

References (65)

1. Adamo ML, Ben Hur H, Roberts CT, Jr., LeRoith D. 1991. Regulation of start site usage in the leader exons of the rat insulin-like growth factor-I gene by development, fasting, and diabetes. Mol Endocrinol 5:1677-1686.
2. Akeno N, Robins J, Zhang M, Czyzyk-Krzeska MF, Clemens TL. 2002. Induction of vascular endothelial growth factor by IGF-I in osteoblast-like cells is mediated by the PI3K signaling pathway through the hypoxia-inducible factor-2alpha. Endocrinology 143:420-425. (Pubitemid 34107194)
3. Balemans W, Ebeling M, Patel N, Van HE, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den EJ, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van HW. 2001. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543.
4. Beamer WH, Eicher EM. 1976. Stimulation of growth in the little mouse. J Endocrinol 71:37-45.
5. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. 2005. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583. (Pubitemid 41446595)
6. Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS. 2004. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol Endocrinol 18:1222-1237. (Pubitemid 38591287)
7. Bodine PV, Stauffer B, Ponce-de-Leon H, Bhat RA, Mangine A, Seestaller- Wehr LM, Moran RA, Billiard J, Fukayama S, Komm BS, Pitts K, Krishnamurthy G, Gopalsamy A, Shi M, Kern JC, Commons TJ, Woodworth RP, Wilson MA, Welmaker GS, Trybulski EJ, Moore WJ. 2009. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 44:1063-1068.
8. Canalis E. 1980. Effect of insulinlike growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest 66:709-719. (Pubitemid 10060939)
9. Canalis E. 1994. Skeletal growth factors and aging. J Clin Endocrinol Metab 78:1009-1010.
10. Canalis E. 2005. The fate of circulating osteoblasts. N Engl J Med 352:2014-2016.
11. Canalis E. 2007. Skeletal growth factors. In: Marcus R, Feldman D, Nelson D, Rosen C, editors. Osteoporosis, 3rd edition. San Diego: Academic Press. pp 529-546.
12. Canalis E, Centrella M, McCarthy T. 1988. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 81:1572-1577. (Pubitemid 18131626)
13. Canalis E, Centrella M, Burch W, McCarthy TL. 1989. Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest 83:60-65. (Pubitemid 19048405)
14. Canalis E, Pash J, Gabbitas B, Rydziel S, Varghese S. 1993. Growth factors regulate the synthesis of insulin-like growth factor-I in bone cell cultures. Endocrinology 133:33-38. (Pubitemid 23206371)
15. Canalis E, Economides AN, Gazzerro E. 2003. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218-235. (Pubitemid 36515285)
16. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. 2007. Glucorticoid-induced osteoporosis: Pathophysiology and therapy. Osteoporos Int 18:1319-1328.
17. Centrella M, McCarthy TL, Canalis E. 1991. Activin-A binding and biochemical effects in osteoblast-enriched cultures from fetal-rat parietal bone. Mol Cell Biol 11:250-258. (Pubitemid 21895202)
18. Daluiski A, Engstrand T, Bahamonde ME, Gamer LW, Agius E, Stevenson SL, Cox K, Rosen V, Lyons KM. 2001. Bone morphogenetic protein-3 is a negative regulator of bone density. Nat Genet 27:84-88. (Pubitemid 32044524)
19. Delany AM, Durant D, Canalis E. 2001. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 15:1781-1789. (Pubitemid 32939308)
20. Demambro VE, Clemmons DR, Horton LG, Bouxsein ML, Wood TL, Beamer WG, Canalis E, Rosen CJ. 2008. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology 149:2051-2061. (Pubitemid 351574504)
21. Devlin RD, Du Z, Buccilli V, Jorgetti V, Canalis E. 2002. Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia. Endocrinology 143:3955-3962. (Pubitemid 35244375)
22. Devlin RD, Du Z, Pereira RC, Kimble RB, Economides AN, Jorgetti V, Canalis E. 2003. Skeletal overexpression of noggin results in osteopenia and reduced bone formation. Endocrinology 144:1972-1978. (Pubitemid 36543336)
23. Eckstein F, Pavicic T, Nedbal S, Schmidt C, Wehr U, Rambeck W, Wolf E, Hoeflich A. 2002. Insulin-like growth factor-binding protein-2 (IGFBP-2) overexpression negatively regulates bone size and mass, but not density, in the absence and presence of growth hormone/IGF-I excess in transgenic mice. Anat Embryol (Berl) 206:139-148. (Pubitemid 35478056)
24. Edwards CM, Edwards JR, Lwin ST, Esparza J, Oyajobi BO, McCluskey B, Munoz S, Grubbs B, Mundy GR. 2008. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111:2833-2842.
25. Gazzerro E, Canalis E. 2006. Skeletal actions of insulin-like growth factors. Expert Rev Endocrinol Metab 1:47-56.
26. Gazzerro E, Pereira RC, Jorgetti V, Olson S, Economides AN, Canalis E. 2005. Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. Endocrinology 146:655-665. (Pubitemid 40129821)
27. Gazzerro E, Deregowski V, Stadmeyer L, Gale NW, Economides AN, Canalis E. 2006. Twisted gastrulation, a bone morphogenetic protein agonist/antagonist, is not required for post-natal skeletal function. Bone 39:1252-1260. (Pubitemid 44827936)
28. Gazzerro E, Smerdel-Ramoya A, Zanotti S, Stadmeyer L, Durant D, Economides AN, Canalis E. 2007. Conditional deletion of gremlin causes a transient increase in bone formation and bone mass. J Biol Chem 282:31549-31557. (Pubitemid 350044884)
29. Giustina A, Mazziotti G, Canalis E. 2008. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535-559.
30. Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8:751-764. (Pubitemid 40585297)
31. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D, Klibanski A. 1996. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa. J Clin Endocrinol Metab 81:3864-3870. (Pubitemid 26380388)
32. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A. 2002. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab 87:2883-2891. (Pubitemid 34655358)
33. Grisanti M, Niu QT, Fan W, Asuncion F, Lee J, Steavenson S, Chen Q, Li J, Geng Z, Kostenuik P, Lacey DL, Simonet WS, Ominsky MS, Li X, Richards WG. 2006. Dkk-1 inhibition increases bone mineral density in rodents. J Bone Miner Res 21(Supplement 1): S25.
34. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO. 2005. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168. (Pubitemid 40805677)
35. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 16:3-34.
36. Kaneko H, Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, Toyama Y, Yabe Y, Kumegawa M, Hakeda Y. 2000. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27:479-486. (Pubitemid 30738616)
37. Kansara M, Tsang M, Kodjabachian L, Sims NA, Trivett MK, Ehrich M, Dobrovic A, Slavin J, Choong PF, Simmons PJ, Dawid IB, Thomas DM. 2009. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 119:837-851.
38. Kawano Y, Kypta R. 2003. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116:2627-2634. (Pubitemid 36857216)
39. Krishnan V, Bryant HU, MacDougald OA. 2006. Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202-1209.
40. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, Kiel DP. 1998. Association between insulin-like growth factor I and bone mineral density in older women and men: The Framingham Heart Study. J Clin Endocrinol Metab 83:4257-4262. (Pubitemid 29100118)
41. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. 2008. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869. (Pubitemid 351768804)
42. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588.
43. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72. (Pubitemid 23306021)
44. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM. 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15:928-935. (Pubitemid 40994212)
45. Mansukhani A, Ambrosetti D, Holmes G, Cornivelli L, Basilico C. 2005. Sox2 induction by FGF and FGFR2 activating mutations inhibits Wnt signaling and osteoblast differentiation. J Cell Biol 168:1065-1076. (Pubitemid 40491176)
46. Misra M, Klibanski A. 2006. Anorexia nervosa and osteoporosis. Rev Endocr Metab Disord 7:91-99.
47. Miyazono K. 1999. Signal transduction by bone morphogenetic protein receptors: Functional roles of Smad proteins. Bone 25:91-93. (Pubitemid 29322068)
48. Mochizuki H, Hakeda Y, Wakatsuki N, Usui N, Akashi S, Sato T, Tanaka K, Kumegawa M. 1992. Insulin-like growth factor-I supports formation and activation of osteoclasts. Endocrinology 131:1075-1080.
49. Morvan F, Boulukos K, Clement-Lacroix P, Roman RS, Suc-Royer I, Vayssiere B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G. 2006. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21:934-945. (Pubitemid 43788000)
50. Ning Y, Schuller AG, Bradshaw S, Rotwein P, Ludwig T, Frystyk J, Pintar JE. 2006. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein- 3, -4, and -5. Mol Endocrinol 20:2173-2186. (Pubitemid 44286712)
51. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW, Haigis B, Ucran J, Kumar R, Pobre E, Grinberg A, Werner ED, Glatt V, Stadmeyer L, Smith D, Seehra J, Bouxsein ML. 2008. A soluble activin type IIA receptor induces bone formation and improves skeletal integrity. Proc Natl Acad Sci USA 105:7082-7087. (Pubitemid 351754533)
52. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. 2000. Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of beta-catenin. Proc Natl Acad Sci USA 97:12103-12108. (Pubitemid 30815145)
53. Silha JV, Mishra S, Rosen CJ, Beamer WG, Turner RT, Powell DR, Murphy LJ. 2003. Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. J Bone Miner Res 18:1834-1841. (Pubitemid 37322561)
54. Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R, Goffin V, Coschigano K, Gaillard-Kelly M, Kopchick J, Baron R, Kelly PA. 2000. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 106:1095-1103. (Pubitemid 30835011)
55. Tanner SJ, Hefferan TE, Rosen CJ, Conover CA. 2008. Impact of pregnancy-associated plasma protein - A deletion on the adult murine skeleton. J Bone Miner Res 23:655-662.
56. Teitelbaum SL. 2000. Bone resorption by osteoclasts. Science 289:1504-1508.
57. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD, Jr. 2003. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483-2494.
58. Westendorf JJ, Kahler RA, Schroeder TM. 2004. Wnt signaling in osteoblasts and bone diseases. Gene 341:19-39. (Pubitemid 39335880)
59. Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA. 2005. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 280:2498-2502. (Pubitemid 40189350)
60. Yakar S, Canalis E, Sun H, Mejia W, Kawashima Y, Nasser P, Courtland HW, Williams V, Bouxsein M, Rosen C, Jepsen KJ. 2009. Serum IGF-1 determines skeletal strength by regulating sub-periosteal expansion and trait interactions. J Bone Miner Res 24:1481-1482.
61. Zhang Y, Zhang Q. 2009. Bone morphogenetic protein-7 and gremlin: New emerging therapeutic targets for diabetic nephropathy. Biochem Biophys Res Commun 383:1-3.
62. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. 2002. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 277:44005-44012. (Pubitemid 36157826)
63. Zhang M, Faugere MC, Malluche H, Rosen CJ, Chernausek SD, Clemens TL. 2003. Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. J Bone Miner Res 18:836-843. (Pubitemid 37294966)
64. Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. 2000. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: Increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 141:2674-2682. (Pubitemid 32269089)
65. Zimmerman LB, Jesus-Escobar JM, Harland RM. 1996. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86:599-606.